Abstract. Hyaluronic acid (HA) is essential for the function of extracellular matrices in both hard and soft periodontal components. HA plays an important role in the mechanisms underlying inflammation and wound healing. HA is located in periodontal tissues in differing amounts, including non-mineralized tissues, such as gingiva and periodontal ligament, and lower levels located in mineralized tissues, such as cementum and alveolar bone. According to preliminary findings, HA exhibits potential in the regulation of periodontal tissue regeneration and in the treatment of periodontal disease. HA promotes symptomatic relief in both marginal gingiva and deeper periodontal tissues. The present review aimed to examine the role of HA in periodontal therapy, and investigate the current literature supporting its use in periodontal regeneration.

1. Introduction

Hyaluronic acid (HA), also referred to as hyaluronan, is one of the most predominant glycosaminoglycans in the extracellular matrix (1). In 1934, Karl Meyer and John Palmer extracted HA from the vitreous fluid of the eye of a cow (2). ‘HA’, as it originated from hyalos (meaning glass in Greek), possessed two sugar molecules, one of them being uronic acid. Moreover, this linear polysaccharide exhibits numerous repeating disaccharide units (3). Notably, a healthy adult (weight, 70 kg) possesses ~15 g HA in the body (4). The majority of cells in the human body synthesize HA; thus, it may play a role in a variety of key biological processes. This evidence demonstrates the potential of HA as a therapeutic option (5).

At present, HA is used for the treatment of chronic inflammatory diseases. Notably, periodontal disease is an inflammatory disease involving the periodontium. The mineralized periodontal tissues of alveolar bone and cementum contain very little HA; however, it is necessitated by the extracellular matrix of the gingiva and the periodontal ligament (4). Wound healing is accelerated following treatment with HA, due to the subsequent impact on HA receptors, which play a role in cellular migration, angiogenesis and inflammation. HA relieves symptoms, both in the marginal gingiva and deeper periodontal tissues (6). This wound-healing characteristic of HA has also been used in different periodontal treatments, involving non-surgical and surgical therapy, and soft and hard tissue regeneration. Moreover, HA plays a crucial role in cell signaling and hemostasis, and manages the cell-matrix and cell-cell exchanges. HA also plays role in the inflow and outflow of nutrients and waste products (7). Notably, HA may be used in periodontal research due to the extensive scope of applications, which are summarized in the present review. No systemic search strategy was performed for the review. An online search was performed for studies, without a specific time frame, using key words (hyaluronic acid, periodontics, periodontal therapy, periodontal regeneration and wound healing) in combination.

2. Properties of HA

Hyaluronic acid (HA), also referred to as hyaluronan, is one of the most predominant glycosaminoglycans in the extracellular matrix (1). In 1934, Karl Meyer and John Palmer extracted HA from the vitreous fluid of the eye of a cow (2). ‘HA’, as it originated from hyalos (meaning glass in Greek), possessed two sugar molecules, one of them being uronic acid. Moreover, this linear polysaccharide exhibits numerous repeating disaccharide units (3). Notably, a healthy adult (weight, 70 kg) possesses ~15 g HA in the body (4). The majority of cells in the human body synthesize HA; thus, it may play a role in a variety of key biological processes. This evidence demonstrates the potential of HA as a therapeutic option (5).

At present, HA is used for the treatment of chronic inflammatory diseases. Notably, periodontal disease is an inflammatory disease involving the periodontium. The mineralized periodontal tissues of alveolar bone and cementum contain very little HA; however, it is necessitated by the extracellular matrix of the gingiva and the periodontal ligament (4). Wound healing is accelerated following treatment with HA, due to the subsequent impact on HA receptors, which play a role in cellular migration, angiogenesis and inflammation. HA relieves symptoms, both in the marginal gingiva and deeper periodontal tissues (6). This wound-healing characteristic of HA has also been used in different periodontal treatments, involving non-surgical and surgical therapy, and soft and hard tissue regeneration. Moreover, HA plays a crucial role in cell signaling and hemostasis, and manages the cell-matrix and cell-cell exchanges. HA also plays role in the inflow and outflow of nutrients and waste products (7). Notably, HA may be used in periodontal research due to the extensive scope of applications, which are summarized in the present review. No systemic search strategy was performed for the review. An online search was performed for studies, without a specific time frame, using key words (hyaluronic acid, periodontics, periodontal therapy, periodontal regeneration and wound healing) in combination.

2. Properties of HA

Hyaluronic acid (HA) plays a variety of roles in the body, leveraging physico-chemical and biological properties. These biological functions vary from basic structural roles in the extracellular matrix to developmental regulation via effects on cell behaviour through tissue macro and microenvironment control. These functions of HA also exert direct receptor-mediated effects on gene expression (8,9). HA exhibits hygroscopic and viscoelastic properties. Hydrogen and adjacent carboxyl and N-acetyl group bonding occurs after HA is absorbed by an aqueous solution, allowing HA to maintain conformational rigidity through water retention (10). Through maintaining...
gaps and preserving surfaces, HA modifies the surrounding cellular and extracellular micro and macro environments. HA exhibits bacteriostatic activity, and this was demonstrated to be the highest when high concentrations of medium and lower molecular weight HA were used (11). HA is biocompatible and non-immunogenic in nature. Esterification and cross-linking are two modifications of HA that provide a gel-like structure and rigidity for cell seeding (12). In addition, HA exhibits anti-inflammatory properties. It performs scavenging actions, through the clearing of prostaglandins, metalloproteinases and other bioactive molecules (12). HA also exhibits anti-edematous properties associated with osmotic action (13), and antioxidant properties. HA scavenges reactive oxygen species; thus, stabilizing the granulation tissue matrix (14).

3. Synthesis of HA

HA is a negatively charged glycosaminoglycan that differs from other glycosaminoglycans. HA synthesis occurs in the cellular plasma membrane in mammals, whereas glycosaminoglycan synthesis often occurs in the Golgi apparatus. Moreover, HA synthesis occurs via three hyaluronan synthase isoenzymes (HAS1, 2 and 3) (7). HA exhibits a high molecular weight of $10^3-10^4$ kDa, a length of 2-25 µm, and it does not contain any sulphate groups (8). The synovial fluid, epidermis, umbilical cord and other tissues exhibit the highest concentrations of HA, while the blood serum exhibits the lowest concentration (15). A membrane-bound protein present in plasma membranes produces HA through the transportation of activated monosaccharides to glycosaminoglycan chains, and the release of uridine diphosphate, secreted directly into the extracellular space. Lymphatic drainage into the circulatory system or local metabolism causes HA turnover in tissues. Depending on its removal, HA exhibits a tissue half-life ranging from 12 h to 2-3 days (16).

4. Role of HA in wound healing

HA plays a role in numerous physiological and biological processes, serving as a structural component of cartilage and other tissues. To produce proteoglycans, HA interacts with proteins rich in numerous forms of glycosaminoglycans. It increases inflammatory cell and extracellular matrix infiltration, assisting inflammation. Thus, HA exhibits the potential to impact cellular behaviour via influencing the environment surrounding cells (16). HA is engaged in numerous cell functions which increase tissue healing, such as cell proliferation, locomotion and recognition. This makes HA increasingly susceptible to colonization by tissue repair cells (17). In its highly purified form, HA has been used in medicine for a number of years, due to its physiochemical characteristics and non-immunogenicity. As HA retains water in large amounts, it affects and improves tissue regeneration; thus, preventing the production of scabs and scars (18,19). It has been proposed that HA stimulates angiogenesis, leading to increased levels of wound healing in the bone matrix. At a low molecular weight, HA is angiogenic, whereas at a high molecular weight, HA is anti-angiogenic (20). High molecular weight HA enhances osteo-induction or bone production during wound healing (21). Results of previous studies demonstrated that exogenous HA exerted satisfying wound healing benefits (22-24). In cosmetic dermatology, HA is also used as a dermal filler (25). As it forms an integral part of cell migration, organogenesis and development, HA exhibits potential in tissue engineering (26). The esterification and cross-linking of HA are two modifications that provide the gel-like structure and rigidity for cell seeding. These biopolymers are biodegradable which help fibroblasts, chondrocytes and mesenchymal stem cells to proliferate (27). HA has been employed as a chemotherapeutic agent in the treatment of gingivitis. Moreover, osseointegration of dental implants indicates the involvement of HA (28). As HA exhibits bone induction properties, it may exhibit potential as a biomaterial scaffold in guided bone regeneration and tissue engineering (29). In 2022, Ibraheem et al (30) demonstrated improved wound healing in extraction socket wounds following treatment with HA. Moreover, HA exhibited dose-dependent bacteriostatic effects on a range of microorganisms in the planktonic phase (31).

Hyaluronan generates cell responses via interaction with cell receptors. Notably, there are numerous different cell receptors involved in HA signaling. The most common receptor involved in HA signaling is CD44 (32). CD44 signaling plays a crucial role in wound healing, as CD44 in fibroblasts is required for emigration into the affected region (33). Notably, receptor for hyaluronan-mediated motility (RHAMM), also known as CD168, plays a key role in signaling. RHAMM-hyaluronan interactions are vital for tissue repair and inflammation (34). In addition, hyaluronan receptor for endocystosis is involved in hyaluronan endocytosis, and lymphatic vessel endothelial hyaluronan receptor 1 plays a role in the regulation of tissue hydration and other biochemical properties, via the absorption of HA in the lymphatic system (35,36).

Toll-like receptors are involved in innate immune response, tissue metabolism and tissue haemostasis (37). Toll-like receptors prompt the synthesis of defesins, which possess antibacterial properties and employ regenerative stimuli for cells (38). The molecular weight of HA is an important aspect in HA signaling. Notably, HA induces different signaling pathways at different molecular weights (39).

5. Role of HA and overview of studies in periodontal therapy

HA is located in the periodontium in differing amounts. There are higher levels in the gingiva and periodontal ligament, compared with the cementum and alveolar bone. Moreover, high amounts of HA in the circulatory blood serum represent a serum overload factor of gingival crevicular fluid (40).

Scaling and root planing (SRP) exerts a positive effect on periodontal parameters, as it decreases the pathogens present in the periodontal pocket and alters the microflora to be less pathogenic (41). Results of previous studies investigating SRP combined with non-mechanical therapy demonstrated that the use of local or systemic antibacterial medicines further improved clinical parameters (42,43). However, systemic antibiotics should not be utilized to treat all types of periodontitis. Limiting the use of systemic antibiotics is vital as the development of resistance and unwarranted drug interactions may occur. In patients with gingivitis and chronic periodontitis, HA is utilized as an adjuvant therapy following SRP. Treatment
| Study                  | Sample size | HA Form          | Intervention          | Inference                                           | Periodontal Therapy               |
|-----------------------|-------------|------------------|-----------------------|-----------------------------------------------------|-----------------------------------|
| Nguyen et al, 2021    | 28 chronic  | 0.2% HA gel      | HA + SRP vs. SRP      | HA showed a greater reduction in BOP and PPD         | Non-surgical periodontal therapy  |
| Al-Shammari et al, 2018 | 24 chronic | 0.8% HA gel      | HA + SRP vs. SRP      | HA showed a greater reduction in BOP and PPD         | Non-surgical periodontal therapy  |
| Rajan et al, 2014     | 33 chronic  | HA gel           | HA + SRP vs. SRP      | HA showed a greater reduction in BOP and PPD         | Non-surgical periodontal therapy  |
| Pilloni et al, 2019   | 30 patients | HA gel           | HA + CAF vs. CAF      | 80% complete root coverage for HA and PPD           | Recession coverage                |
| Kumar et al, 2014     | 10 patients | HA gel           | HA + CAF vs. CAF      | HA group clinically more stable                      | Recession coverage                |
| Pitale et al, 2021    | 25 patients | Injection        | -                     | Significant difference in black triangle height and width | Papilla regeneration            |
| Mansouri et al, 2013  | 21 interdental | HA gel       | -                     | 43% of samples showed SRP highest improvement followed by the HA and CHX groups | Papilla regeneration            |
| Babgi et al, 2020     | 15 single-rooted teeth | HA gel | SRP or EDTA or CHX gel | HA showed significantly greater CAL gain and bone defect fill | Root conditioning               |
| Mamajiwala et al, 2021 | 20 chronic | HA gel           | HA gel + OFD vs. OFD + Placebo | HA showed significantly greater CAL gain and bone defect fill | Regenerative therapy            |
| Bhowmik and Rao, 2021 | 32 graftable defects | HA gel    | HA + NHA bone graft (H-NHA) vs. NHA alone | H-NHA group showed a greater reduction in PPD and defect depth | Regenerative therapy            |
| Briguglio et al, 2013 | 40 subjects with a two-wall infrabony defect | HA gel | HA + OFD vs. OFD | Test group showed significantly greater CAL gain and PPD | Regenerative therapy            |
| Sehdev et al, 2016    | 24 infrabony defects | Esterified HA in the form of fibers | HA + biodegradable membrane vs. biodegradable membrane alone | HA showed significantly higher CAL of 2.20 mm | Regenerative therapy            |
| Sánchez-Fernández et al, 2021 | 100 dental implants | HA gel | HA vs. excipient-based gel vs. no gel | PPD was significantly lower in the HA group | Therapy for peri-implantitis cases |
| Dogan et al, 2017     | 13 systemically healthy patients requiring bilateral two-stage maxillary sinus augmentation (residual crest height ≤4 mm) | HA matrix | Hyaluronic matrix and collagenated heterologous bone graft vs. collagenated heterologous bone graft | Higher percentage of new bone formed in the HA group after 4 months | Sinus lift augmentation |

HA, hyaluronic acid; SRP, scaling and root planing; BOP, bleeding on probing; PPD, probing pocket depth; CAF, coronally advanced flap; EDTA, ethylenediaminetetraacetic acid; CHX, chlorhexidine; OFD, open flap debridement; NHA, nanohydroxyapatite; CAL, clinical attachment level.
with HA results in a reduction in prostaglandins, metalloproteinases and bioactive materials. This results in the impediment of tissue destruction; thus, promoting healing (44).

Notably, Sahayata et al (45) used 0.2% HA gel (Gengigel®) topically in patients with gingivitis. Results of this previous study demonstrated that HA treatment led to decreased gingival bleeding, reduced gingival fluid flow and improved gingival health (43,44). Moreover, Pilloni et al (46) investigated the effects of HA on periodontal parameters in patients with periodontitis. Results of this previous study demonstrated improved outcomes in the HA group compared with the non-HA group, indicated by significant improvements in bleeding on probing (46). In addition, Pistorius et al (47) also demonstrated improvements in bleeding following treatment with HA. Eick et al (48) evaluated the effects of HA with SRP and SRP alone in patients with chronic periodontitis. Results of this previous study demonstrated a significantly higher reduction in probing pocket depth (PPD) in the SRP + HA group, compared with the use of SRP alone (48).

Improvements have been observed in healing, periodontal indices and clinical attachment level (CAL) following treatment with HA. In a split-mouth study, Al-Shammari et al (49) evaluated the effects of SRP + HA and SRP alone in patients with chronic periodontitis. Improvements in gingival indices, CAL and PPD were observed following 6 and 12 weeks in the test group (49). In addition, Madkour et al (50) assessed the effects of HA in patients with chronic periodontitis under medication. Comparable with the results obtained by Al-Shammari et al (49), the levels of gingival indices, PPD and CAL were improved in both groups, but these levels were most improved in the SRP + HA group (50). Eliezer et al (51) also conducted a systematic review, which demonstrated that HA offers beneficial effects in pocket depth reduction, CAL gain and reduction in bleeding on probing during both surgical and non-surgical periodontal therapy.

HA improved CAL and boosted keratinization. Treatment with injectable HA gel of various doses led to improvements in papillary regeneration, as HA promotes neovascularization (52). Çankaya and Tamam compared the interdental papillary fill after HA was injected into the maxillary and mandibular jaws. The injection was delivered until the color of the gingiva changed to white. After 3, 12 and 24 months, the interdental area demonstrated 54.21, 73.22 and 79.35% coverage remaining in the mandible, and 57.24, 71.40 and 78.71% coverage remaining in the maxilla, respectively (52). Hyaluronan promotes fibroblast attachment to the cementum, while also acting as an antibacterial agent. Moreover, sodium hyaluronate enhances chemical signaling between cells. As a result, sodium hyaluronate is often used in the guided tissue regeneration membrane (GTR) (53). Notably, Vanden Bogaerde (54) examined the clinical effectiveness of esterified HA fibers in the treatment of 18 periodontal defects. The mean PPD was decreased by 5.8 mm after a follow-up of 12 months, and the CAL increase was 2.8 mm (54). In a histological examination in experimental animals, novel alveolar bone growth was observed in bone lesions (55). In 2022, a systemic review by Rodríguez-Aranda et al (56) also demonstrated favourable results with HA in periodontal regeneration. This systemic review revealed improvements in terms of CAL, PPD, BOP, and radiographic parameters, when HA was used alone or in combination with bone graft or other biomaterials (56).

Collectively, the results of previous studies have demonstrated the effective use of HA in periodontal therapy. An overview of studies using HA as a periodontal therapeutic intervention with different sample sizes and HA forms are presented in Table I (49,57-69).

6. Conclusion

HA is a vital biomaterial used in periodontal therapy. Treatment with HA leads to clinical improvement in patients with gingivitis, periodontitis, implants and periodontal defects. Treatment with HA accelerates wound healing, resulting in improved postoperative results and high levels of patient comfort. However, further research into the therapeutic effects of HA in periodontal disease is required. This will further determine the specific uses, the optimal administration of HA for the postoperative treatment of periodontal conditions and the potential for complete periodontal tissue regeneration.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors’ contributions

AB, HyF, HaF and WI conceived the review. AB performed the literature search. AB, HyF, HaF and WI wrote the manuscript. HC, SP and AB reviewed and edited the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Amorim S, Reis CA, Reis RL and Pires RA: Extracellular matrix mimics using hyaluronan-based biomaterials. Trends Biotechnol 39: 90-104, 2021.
2. Meyer K and Palmer JW: The polysaccharide of the vitreous humor. J Biol Chem 107: 629-634, 1934.
3. Bansal J, kede SD and Anand S: Hyaluronic acid: A promising mediator for periodontal regeneration. Indian J Dent Res 21: 575-578, 2010.

4. Aya IM, Akbal D, Alkaldir D, Bozoglan A, Ertugrul AS and Demir H: Evaluation of biochemical and clinical effects of hyaluronic acid on non-surgical periodontal treatment: A randomized controlled trial. J Med Sci 189: 1485-1494, 2020.

5. Abatangelo G, Vindigni V, Avruscio G, Pandis L and Brun P: Hyaluronic acid: Redefining its role. Cells 9: 1743, 2020.

6. Casadeo MD, Motha P, Vella P, Sabatino L, Capuanu F, Salvellini B, Lopez MA, Carinci F and Salvellini F: Hyaluronic acid: Perspectives in dentistry. A systematic review Int J Immunopathol Pharmacol 29: 572-582, 2016.

7. Vigetti D, Karousou E, Viola M, Deleonibus S, De Luca G and Pasi A: Hyaluronan: Biosynthesis and signaling. Biochim Biophys Acta 1840: 2452-2459, 2014.

8. Toole BP: Hyaluronan is not just a goo! J Clin Invest 106: 335-336, 2000.

9. Stern RS, Asahi AA and Sugahara KN: Hyaluronan fragments: An information rich system. Eur J Cell Biol 85: 699-715, 2006.

10. Sutherland IW: Novel and established applications of microbial polysaccharides. Trends Biotechnol 16: 41-46, 1998.

11. Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A and Bernard GW: Bacteriostatic effects of hyaluronic acid. J Periodontol 70: 1574-1579, 1999.

12. Laurent TC, Laurent UB and Fraser JR: Functions of hyaluronan. J Intern Med 242: 27-33, 1997.

13. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

14. Waddington RJ, Moseley R and Embery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.

15. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

16. Fraser JR, Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

17. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Greenley AH: TGF-β1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. Cornea 12: 433-436, 1993.

18. Waddington RJ, Moseley R and Embbery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.

19. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

20. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

21. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

22. Waddington RJ, Moseley R and Embbery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.

23. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

24. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

25. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

26. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

27. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

28. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

29. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

30. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

31. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

32. Waddington RJ, Moseley R and Embbery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.

33. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

34. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

35. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

36. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

37. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

38. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

39. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

40. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

41. Waddington RJ, Moseley R and Embbery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.

42. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

43. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

44. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA and Fraser JRE: The properties and turnover of hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

45. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

46. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

47. Waddington RJ, Moseley R and Embbery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.

48. Laurent TC and Fraser JRE: The properties and turnover of hyaluronan. Ciba Found Symp 124: 9-29, 1986.

49. Fraser JR, Laurent TC and Laurent UB: Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997.

50. Waddington RJ, Moseley R and Embbery G: Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151, 2000.
52. Turgut Çankaya Z and Tamam E: An examination of the 2-year results obtained from hyaluronic acid filler injection for interdental papilla losses. Quintessence Int 51: 274-284, 2020.

53. Aveic S, Craveiro RB, Wolf M and Fischer H: Current trends in in vitro modeling to mimic cellular crosstalk in periodontal tissue. Adv Healthc Mater 10: e2001269, 2021.

54. Vanden Bogaerde L: Treatment of infrabony periodontal defects with esterified hyaluronic acid: Clinical report of 19 consecutive lesions. Int J Periodontics Restorative Dent 29: 315-323, 2009.

55. Sukumar S and Ivo Držíhal E: Hyaluronic acid and periodontitis. Acta Medica (Hradec Kralove) 50: 225-228, 2007.

56. Rodríguez-Aranda M, Ibora-Badia I, Alpiste-Illueca F and Lopez-Roldan A: Hyaluronic acid for periodontal tissue regeneration in infrabony defects. A systematic review. Dentistry Review 2: 100057, 2022.

57. Nguyen TT, Ho HT, Huynh NC, Dien VHA and Vo TL: Hyaluronic acid 0.2% application enhanced periodontitis treatment in non-surgical phase. J Stoma 74: 76-83, 2021.

58. Rajan P, Baramappa R, Rao NM, Pavuluri AK, P I and Rahaman SM: Hyaluronic Acid as an adjunct to scaling and root planing in chronic periodontitis. A randomized clinical trial. J Clin Diagn Res 8: ZC11-ZC14, 2014.

59. Pilloni A, Schmidlin PR, Sahrmann P, Sculean A and Rojas MA: Effectiveness of adjunctive hyaluronic acid application in coronally advanced flap in Miller class I single gingival recession sites: A randomized controlled clinical trial. Clin Oral Investig 23: 1133-1141, 2019.

60. Kumar R, Srinivas M, Pai J, Suragimath G, Prasad K and Polepalle T: Efficacy of hyaluronic acid (hyaluronan) in root coverage procedures as an adjunct to coronally advanced flap in Miller's Class I recession: A clinical study. J Indian Soc Periodontol 18: 746-750, 2014.

61. Pitale U, Pal PC, Thakare G, Verma M, Dhakad S and Pandey R: Minimally invasive therapy for reconstruction of lost interdental papilla by using injectable hyaluronic acid filler. J Indian Soc Periodontol 25: 22-28, 2021.

62. Sadat Mansouri S, Ghasemi M, Salmani Z and Shams N: Clinical application of hyaluronic acid gel for reconstruction of interdental papilla at the esthetic zone. J Iran Dent Asso 25: 208-213, 2013.

63. Babgi W, Alhajaji M, Al-Mehmadi L, Elbaqli R, Khayat N, Aldahlawi S and Youssef AR: Effect of root conditioning agents hyaluronic acid, EDTA and chlorhexidine on the attachment of human gingival fibroblasts to healthy root surface. Saudi Dent J 33: 342-347, 2021.

64. Mamajiwala AS, Sethi KS, Raut CP, Karde PA and Mamajiwala BS: Clinical and radiographic evaluation of 0.8% hyaluronic acid as an adjunct to open flap debridement in the treatment of periodontal intrabony defects: Randomized controlled clinical trial. Clin Oral Investig 25: 5257-5271, 2021.

65. Bhowmik E and Rao DPC: Clinicoradiographic evaluation of hyaluronan-nano hydroxyapatite composite graft in the management of periodontal infrabony defects. J Indian Soc Periodontol 25: 220-227, 2021.

66. Briguglio F, Briguglio E, Briguglio R, Caiero C and Isola G: Treatment of infrabony periodontal defects using a resorbable biopolymer of hyaluronic acid: A randomized clinical trial. Quintessence Int 44: 231-240, 2013.

67. Sehdev B, Bhongade ML and Ganji KK: Evaluation of effectiveness of hyaluronic acid in combination with bioresorbable membrane (poly lactic acid-poly glycolic acid) for the treatment of infrabony defects in humans: A clinical and radiographic study. J Indian Soc Periodontol 20: 50-56, 2016.

68. Sánchez-Fernández E, Magán-Fernández A, O'Valle F, Bravo M and Mesa F: Hyaluronic acid reduces inflammation and crevicular fluid IL-1β concentrations in peri-implantitis: A randomized controlled clinical trial. J Periodontal Implant Sci 51: 63-74, 2021.

69. Dogan E, Dursun E, Tosun E, Bilgic E, Akman AC, Orhan K, Celik HH, Korkusuz P and Caglayan F: Evaluation of hyaluronic matrix efficacy in sinus augmentation: A randomized-controlled histomorphometric and micro-computed tomography analysis. Int J Oral Maxillofac Surg 46: 931-937, 2017.